ClinicalTrials.gg
CompletedNCT04630028UNIFI JrUpdated Oct 20, 2026Results posted

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Phase 3 interventional study of Ustekinumab Dose Based on BSA and Body Weight and Matching Placebo in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Completed at 58 sites in 9 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 20, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
18th of 28
112 · median 205
Started
2021
with 3 others
Phase 3
15 of 43
2 open now
Registered
25th of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 25th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with moderately to severely active UC.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable on the basis of physical examination, medical history, and vital signs, performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator
  • Must have had UC diagnosed prior to screening
  • Have moderately to severely active UC, defined as a baseline Mayo score of 6 through 12, inclusive, with a screening Mayo endoscopy subscore greater than or equal to (>=) 2 as determined by a central review of the video of the endoscopy
  • A participant who has had extensive colitis for >= 8 years, or disease limited to the left side of the colon for >= 10 years, must: a) have had a full colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study intervention or b) have a full colonoscopy with surveillance for dysplasia as the baseline endoscopy during the screening period. Results from these surveillance must be negative for dysplasia (low-grade, high-grade, or indeterminant) prior to the first administration of study intervention
  • Females of must have a negative highly sensitive urine pregnancy test at screening and at Week I-0 prior to study intervention administration

Exclusion criteria

Exclusion Criteria:

  • Have UC limited to the rectum only or to less than (\<) 20 centimeter (cm) of the colon
  • Presence or history of colonic or small bowel obstruction within 6 months prior to screening, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy)
  • Have a history of latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis, or have had a nontuberculous mycobacterial infection prior to screening
  • Presence or history of any including presence or history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (example, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas) and monoclonal gammopathy of undetermined significance, or hepatomegaly or splenomegaly
  • Has known allergies, , or intolerance to ustekinumab or its
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Induction Period (I): Ustekinumab

    All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square \[mg/m\^2\]) or weight-tiered induction dose (milligram per kilogram \[mg/kg\]).

    Drug: Ustekinumab Dose Based on BSA and Body Weight

  • Experimental
    Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)

    Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.

    Drug: Ustekinumab Dose Based on BSA and Body Weight · Drug: Matching Placebo

  • Experimental
    Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)

    Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.

    Drug: Ustekinumab Dose Based on BSA and Body Weight · Drug: Matching Placebo

Interventions

  • DrugUstekinumab Dose Based on BSA and Body Weight

    Drug page: UstekinumabStudies of UstekinumabUstekinumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per BSA and body weight Ustekinumab will be administered SC and IV.

    Also known as: STELARA

  • DrugMatching Placebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Global: Percentage of Participants With Clinical Remission at Induction Week 8

    Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Induction Week 8

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AE occurring at or after the initial administration of study intervention.

    Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)

  3. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

    Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of study intervention.

    Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)

  4. Number of Participants With AEs Leading to Discontinuation of Study Intervention

    Number of participants with AEs leading to discontinuation of study intervention were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)

  5. Number of Participants With Adverse Events of Special Interest (AESIs)

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active Tuberculosis (TB), or opportunistic infection occurring after the first administration of study intervention.

    Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)

  6. Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology

    Number of participants with abnormalities in clinical laboratory parameters with increased or decreased hematology parameters such as hemoglobin, anemia, lymphocyte count, platelet count, leukocytosis, white blood cells, were reported. Grades 0-4 were based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.

    Time frame: Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)

  7. Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry

    Number of participants with abnormalities in clinical laboratory parameters with increased or decreased chemistry parameters such as Alanine Aminotransferase, Aspartate Aminotransferase, Hypoalbuminemia, Alkaline Phosphatase, Blood Bilirubin, Creatinine, Gamma-Glutamyl Transferase, Hyperkalemia, Hypokalemia, Hypernatremia, Hyponatremia were reported. Grades 0-4 were based on NCI-CTCAE version 5.0 where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.

    Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)

  8. Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)

    Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) injection-site reactions (Maintenance Period) were reported.

    Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)

  9. Serum Ustekinumab Concentrations

    Serum ustekinumab concentrations were reported. PK= pharmacokinetic.

    Time frame: Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44

Secondary outcomes

  1. Percentage of Participants With Clinical Response at Induction Week 8

    Clinical response was defined as a decrease from induction baseline in the Modified Mayo score by \>=30 percent (%) and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore \>=1 or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Induction Week 8

  2. Percentage of Participants With Symptomatic Remission at Induction Week 8

    Symptomatic remission was defined as a Mayo stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal) and a rectal bleeding subscore of 0 (no blood seen), where the stool frequency subscore had not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Induction Week 8

  3. Percentage of Participants With Clinical Remission at Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score

    Percentage of participants with clinical remission at Induction Week 8 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50 % of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.

    Time frame: Induction Week 8

  4. Percentage of Participants With Endoscopic Improvement at Induction Week 8

    Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.

    Time frame: Induction Week 8

  5. Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Induction Week 8

    Histologic-endoscopic mucosal improvement based on Geboes score (GS) was defined as achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system) and endoscopic improvement (Mayo subscore of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Higher score, more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore determined during central review, each subscore graded from 0 (normal) to 3 (severe). Individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher score=more severe disease.

    Time frame: Induction Week 8

  6. Percentage of Participants With Clinical Remission at Maintenance Week 44

    Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Maintenance Week 44 (Study Week 52)

  7. Percentage of Participants With Symptomatic Remission at Maintenance Week 44

    Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Maintenance Week 44 (Study Week 52)

  8. Percentage of Participants With Clinical Remission at Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score

    Percentage of participants with clinical remission at Maintenance Week 44 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50% of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number of stools per 24 hours (0-2 =0, 3-5 =5, 6-8 =10, \>8 =15); nocturnal bowel movement (no =0, yes =10); activity level (no limitation of activity =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.

    Time frame: Maintenance Week 44 (Study Week 52)

  9. Percentage of Participants With Endoscopic Improvement at Maintenance Week 44

    Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.

    Time frame: Maintenance Week 44 (Study Week 52)

  10. Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44

    Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Maintenance Week 44 (Study Week 52)

  11. Percentage of Participants With Clinical Remission at Maintenance Week 44 and Not Receiving Corticosteroids for At Least 90 Days Prior to Maintenance Week 44 Among Participants Who Received Corticosteroids at Induction Week 0

    Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Maintenance Week 44 (Study Week 52)

  12. Percentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8

    Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

    Time frame: Maintenance Week 44 (Study Week 52)

  13. Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44

    Histologic-endoscopic mucosal improvement based on Geboes Score: achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system), endoscopic improvement (Mayo sub-score of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; Grade 5, erosions or ulceration. Higher score indicated more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding, endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.

    Time frame: Maintenance Week 44 (Study Week 52)

07

Results

Posted Oct 20, 2026

Participant flow

Induction Period (Week I-0 to Week I-8)
Participant flow — Induction Period (Week I-0 to Week I-8)
MilestoneInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Started11200
Completed10900
Not completed300
Withdrew: Adverse event100
Withdrew: Lack of efficacy100
Withdrew: Initiated prohibited medication100
Maintenance Period (Week M-0 to M-44)
Participant flow — Maintenance Period (Week M-0 to M-44)
MilestoneInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Started05554
Completed04649
Not completed095
Withdrew: Adverse event021
Withdrew: Lack of efficacy030
Withdrew: Physician decision010
Withdrew: Withdrawal by subject011
Withdrew: Early escape021
Withdrew: Initiated prohibited medication001
Withdrew: Other001

Outcome measures

PrimaryGlobal: Percentage of Participants With Clinical Remission at Induction Week 8

Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Induction Week 8
Reported as:
Number · Percentage of participants
Global: Percentage of Participants With Clinical Remission at Induction Week 8
Percentage of participantsInduction Period: Ustekinumab Intravenous (IV)
Global: Percentage of Participants With Clinical Remission at Induction Week 825 (17.9 to 33.8)
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AE occurring at or after the initial administration of study intervention.

Time frame:
Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Number of Participants With Treatment-emergent Adverse Events (TEAEs)595248
PrimaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of study intervention.

Time frame:
Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)625
PrimaryNumber of Participants With AEs Leading to Discontinuation of Study Intervention

Number of participants with AEs leading to discontinuation of study intervention were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Time frame:
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Discontinuation of Study Intervention
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Number of Participants With AEs Leading to Discontinuation of Study Intervention232
PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs)

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active Tuberculosis (TB), or opportunistic infection occurring after the first administration of study intervention.

Time frame:
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Number of Participants With Adverse Events of Special Interest (AESIs)010
PrimaryNumber of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology

Number of participants with abnormalities in clinical laboratory parameters with increased or decreased hematology parameters such as hemoglobin, anemia, lymphocyte count, platelet count, leukocytosis, white blood cells, were reported. Grades 0-4 were based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.

Time frame:
Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Hemoglobin Increased Grade 01025453
Anemia Grade 0572020
Anemia Grade 1272425
Anemia Grade 21677
Anemia Grade 3231
Lymphocyte Count Increased Grade 01005253
Lymphocyte Count Increased Grade 2120
Lymphocyte Count Decreased Grade 0964744
Lymphocyte Count Decreased Grade 1347
Lymphocyte Count Decreased Grade 2121
Lymphocyte Count Decreased Grade 3111
Platelet Count Decreased Grade 01005452
Platelet Count Decreased Grade 1001
Leukocytosis Grade 01025453
White Blood Cells Decreased Grade 0944338
White Blood Cells Decreased Grade 161111
White Blood Cells Decreased Grade 2204
PrimaryNumber of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry

Number of participants with abnormalities in clinical laboratory parameters with increased or decreased chemistry parameters such as Alanine Aminotransferase, Aspartate Aminotransferase, Hypoalbuminemia, Alkaline Phosphatase, Blood Bilirubin, Creatinine, Gamma-Glutamyl Transferase, Hyperkalemia, Hypokalemia, Hypernatremia, Hyponatremia were reported. Grades 0-4 were based on NCI-CTCAE version 5.0 where Grade 0-Normal, Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe or medically significant but not immediately life-threatening, Grade 4- Life-threatening consequences. Higher grades showed severe abnormality. Only abnormalities where at least one participant had data are reported.

Time frame:
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Alanine Aminotransferase Increased Grade 01075247
Alanine Aminotransferase Increased Grade 1024
Alanine Aminotransferase Increased Grade 2001
Alanine Aminotransferase Increased Grade 3001
Aspartate Aminotransferase Increased Grade 01055347
Aspartate Aminotransferase Increased Grade 1015
Aspartate Aminotransferase Increased Grade 2001
Hypoalbuminemia Grade 01065453
Hypoalbuminemia Grade 1100
Alkaline Phosphatase Increased Grade 01054844
Alkaline Phosphatase Increased Grade 1268
Alkaline Phosphatase Increased Grade 2001
Blood Bilirubin Increased Grade 01025148
Blood Bilirubin Increased Grade 1022
Blood Bilirubin Increased Grade 2513
Creatinine Increased Grade 01035146
Creatinine Increased Grade 1436
Creatinine Increased Grade 2001
Gamma-Glutamyl Transferase Increased Grade 01075350
Gamma-Glutamyl Transferase Increased Grade 2011
Gamma-Glutamyl Transferase Increased Grade 3002
Hyperkalemia Grade 01065049
Hyperkalemia Grade 1133
Hyperkalemia Grade 2011
Hypokalemia Grade 01065352
Hypokalemia Grade 2111
Hypernatremia Grade 01075353
Hypernatremia Grade 1010
Hyponatremia Grade 01075453
PrimaryNumber of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)

Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) injection-site reactions (Maintenance Period) were reported.

Time frame:
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
ParticipantsInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)301
PrimarySerum Ustekinumab Concentrations

Serum ustekinumab concentrations were reported. PK= pharmacokinetic.

Time frame:
Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44
Reported as:
Mean · micrograms per milliliter
Serum Ustekinumab Concentrations
micrograms per milliliterInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Week I-0, Pre-infusion0.020 ± 0.1194——
Week I-0, 1-hour post infusion115.269 ± 30.4642——
Week I-229.157 ± 8.9948——
Week I-415.356 ± 6.9475——
Week I-85.018 ± 3.6498——
Week M-4—6.065 ± 3.77827.405 ± 3.9628
Week M-8—2.401 ± 2.32243.163 ± 2.5936
Week M-12—0.972 ± 1.16886.697 ± 3.4813
Week M-16—5.138 ± 2.75223.125 ± 2.2043
Week M-24—0.935 ± 0.95913.544 ± 2.3097
Week M-32—2.205 ± 2.02743.650 ± 2.3885
Week M-36—1.041 ± 1.36167.626 ± 2.6618
Week M-44—2.439 ± 2.36897.603 ± 2.8930
SecondaryPercentage of Participants With Clinical Response at Induction Week 8

Clinical response was defined as a decrease from induction baseline in the Modified Mayo score by \>=30 percent (%) and \>= 2 points, with either a decrease from baseline in the rectal bleeding subscore \>=1 or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Induction Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Response at Induction Week 8
Percentage of ParticipantsInduction Period: Ustekinumab Intravenous (IV)
Percentage of Participants With Clinical Response at Induction Week 867.0 (57.8 to 75.0)
SecondaryPercentage of Participants With Symptomatic Remission at Induction Week 8

Symptomatic remission was defined as a Mayo stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal) and a rectal bleeding subscore of 0 (no blood seen), where the stool frequency subscore had not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Induction Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Symptomatic Remission at Induction Week 8
Percentage of ParticipantsInduction Period: Ustekinumab Intravenous (IV)
Percentage of Participants With Symptomatic Remission at Induction Week 848.2 (39.2 to 57.4)
SecondaryPercentage of Participants With Clinical Remission at Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score

Percentage of participants with clinical remission at Induction Week 8 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50 % of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.

Time frame:
Induction Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission at Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score
Percentage of participantsInduction Period: Ustekinumab Intravenous (IV)
Percentage of Participants With Clinical Remission at Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score38.4 (29.9 to 47.6)
SecondaryPercentage of Participants With Endoscopic Improvement at Induction Week 8

Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.

Time frame:
Induction Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Endoscopic Improvement at Induction Week 8
Percentage of participantsInduction Period: Ustekinumab Intravenous (IV)
Percentage of Participants With Endoscopic Improvement at Induction Week 830.4 (22.6 to 39.4)
SecondaryPercentage of Participants With Histologic-Endoscopic Mucosal Improvement at Induction Week 8

Histologic-endoscopic mucosal improvement based on Geboes score (GS) was defined as achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system) and endoscopic improvement (Mayo subscore of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Higher score, more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore determined during central review, each subscore graded from 0 (normal) to 3 (severe). Individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher score=more severe disease.

Time frame:
Induction Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Induction Week 8
Percentage of participantsInduction Period: Ustekinumab Intravenous (IV)
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Induction Week 819.6 (13.3 to 28.0)
SecondaryPercentage of Participants With Clinical Remission at Maintenance Week 44

Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and range from 0 to 12, where 3 to 5= mild; 6 to 10= moderate; and 11 to 12= severe; higher scores indicate worsening of disease. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Remission at Maintenance Week 44
Percentage of ParticipantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Clinical Remission at Maintenance Week 4432.5 (20.1 to 48.0)48.7 (33.9 to 63.8)
SecondaryPercentage of Participants With Symptomatic Remission at Maintenance Week 44

Symptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Symptomatic Remission at Maintenance Week 44
Percentage of ParticipantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Symptomatic Remission at Maintenance Week 4457.5 (42.2 to 71.5)74.4 (58.9 to 85.4)
SecondaryPercentage of Participants With Clinical Remission at Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score

Percentage of participants with clinical remission at Maintenance Week 44 as assessed by PUCAI score was reported. Clinical remission as measured by the PUCAI score was a PUCAI score \<10. PUCAI score was intended for pediatric participants with UC. PUCAI consisted of the following 6 subscores with scores as: abdominal pain (no pain =0, pain can be ignored =5, pain cannot be ignored =10); rectal bleeding (none =0, small amount only \[in less than 50% of stools\] =10, small amount with most stools =20, large amount \[\>50% of the stool content\] =30); stool consistency of most stools (formed =0, partially formed =5, completely unformed =10); number of stools per 24 hours (0-2 =0, 3-5 =5, 6-8 =10, \>8 =15); nocturnal bowel movement (no =0, yes =10); activity level (no limitation of activity =0, occasional limitation of activity =5, severely restricted activity =10). PUCAI total score ranges from 0 to 85, with higher scores indicating greater disease severity.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Remission at Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score
Percentage of ParticipantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Clinical Remission at Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) Score57.5 (42.2 to 71.5)71.8 (56.2 to 83.5)
SecondaryPercentage of Participants With Endoscopic Improvement at Maintenance Week 44

Endoscopic improvement was defined as a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Endoscopic Improvement at Maintenance Week 44
Percentage of ParticipantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Endoscopic Improvement at Maintenance Week 4432.5 (20.1 to 48.0)48.7 (33.9 to 63.8)
SecondaryPercentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44

Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Percentage of participantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 4432.5 (20.1 to 48.0)48.7 (33.9 to 63.8)
SecondaryPercentage of Participants With Clinical Remission at Maintenance Week 44 and Not Receiving Corticosteroids for At Least 90 Days Prior to Maintenance Week 44 Among Participants Who Received Corticosteroids at Induction Week 0

Corticosteroid-free clinical remission was defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission at Maintenance Week 44 and Not Receiving Corticosteroids for At Least 90 Days Prior to Maintenance Week 44 Among Participants Who Received Corticosteroids at Induction Week 0
Percentage of participantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Clinical Remission at Maintenance Week 44 and Not Receiving Corticosteroids for At Least 90 Days Prior to Maintenance Week 44 Among Participants Who Received Corticosteroids at Induction Week 041.2 (21.6 to 64.0)56.3 (33.2 to 76.9)
SecondaryPercentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8

Clinical remission was defined by Mayo subscores as: a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity. Baseline was defined as the last observation prior to or at the time of the first study intervention.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8
Percentage of participantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 863.6 (35.4 to 84.8)56.3 (33.2 to 76.9)
SecondaryPercentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44

Histologic-endoscopic mucosal improvement based on Geboes Score: achieving a combination of histologic improvement (neutrophil infiltration in \<5% of crypts, no crypt destruction, no erosions, ulcerations or granulation tissue according to Geboes grading system), endoscopic improvement (Mayo sub-score of 0 or 1 with no friability in endoscopy). GS has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils, eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; Grade 5, erosions or ulceration. Higher score indicated more severe disease. Modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding, endoscopic subscore as determined during central review, each subscore graded from 0 (normal) to 3 (severe). These individual subscores were summed up to give total modified Mayo score range of 0 (normal) to 9 (severe disease), higher scores indicated more severe disease.

Time frame:
Maintenance Week 44 (Study Week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44
Percentage of participantsMaintenance Period: Ustekinumab SC q12wMaintenance Period: Ustekinumab SC q8w
Percentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 4427.5 (16.1 to 42.8)46.2 (31.6 to 61.4)

Adverse events

Collected over All-cause mortality: From screening (-6 weeks) up to Week I-8 (Induction Period); from Week M-0 (Study Week 8) up to Week M-44(Study Week 52) (Maintenance period); Serious and other AEs: From Week I-0 up to Week I-8 (Induction Period); from Week M-0 (Study Week 8) up to Week M-44 (Study Week 52) (Maintenance period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Period: Ustekinumab Intravenous (IV)0/112 (0%)6/112 (5.4%)42/112 (37.5%)
Maintenance Period: Ustekinumab SC Every 12 Weeks (q12w)0/55 (0%)2/55 (3.6%)46/55 (83.6%)
Maintenance Period: Ustekinumab SC Every 8 Weeks (q8w)0/54 (0%)5/54 (9.3%)40/54 (74.1%)
Most frequent serious events
Most frequent serious events
EventInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC Every 12 Weeks (q12w)Maintenance Period: Ustekinumab SC Every 8 Weeks (q8w)
Colitis UlcerativeGastrointestinal disorders2/1120/552/54
AnaemiaBlood and lymphatic system disorders2/1120/551/54
SalmonellosisInfections and infestations0/1120/551/54
Suicidal IdeationPsychiatric disorders0/1120/551/54
MalnutritionMetabolism and nutrition disorders0/1121/550/54
AsthmaRespiratory, thoracic and mediastinal disorders0/1121/550/54
Subcutaneous AbscessInfections and infestations1/1120/550/54
Infusion Related ReactionInjury, poisoning and procedural complications1/1120/550/54
Iron Deficiency AnaemiaBlood and lymphatic system disorders0/1120/550/54
Acute Kidney InjuryRenal and urinary disorders0/1120/550/54
Most frequent other events
Showing 10 of 17
Most frequent other events
EventInduction Period: Ustekinumab Intravenous (IV)Maintenance Period: Ustekinumab SC Every 12 Weeks (q12w)Maintenance Period: Ustekinumab SC Every 8 Weeks (q8w)
Colitis UlcerativeGastrointestinal disorders4/11221/5512/54
Upper Respiratory Tract InfectionInfections and infestations4/11213/5514/54
NasopharyngitisInfections and infestations2/1127/5511/54
AnaemiaBlood and lymphatic system disorders11/1125/558/54
HeadacheNervous system disorders5/1127/553/54
Covid-19Infections and infestations7/1125/552/54
NauseaGastrointestinal disorders2/1121/554/54
Iron Deficiency AnaemiaBlood and lymphatic system disorders2/1124/550/54
HaematocheziaGastrointestinal disorders1/1124/552/54
Respiratory Tract InfectionInfections and infestations0/1124/552/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ustekinumab IV (Induction)
Mean13.2 ± 3.09
Age, Customized
Age, Customized(Participants)Ustekinumab IV (Induction)
2-<12 years30
12-<18 years82
Sex: Female, Male
Sex: Female, Male(Participants)Ustekinumab IV (Induction)
Female61
Male51
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ustekinumab IV (Induction)
Hispanic or Latino1
Not Hispanic or Latino108
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ustekinumab IV (Induction)
American Indian or Alaska Native0
Asian13
Native Hawaiian or Other Pacific Islander0
Black or African American2
White94
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(Participants)Ustekinumab IV (Induction)
BELGIUM13
GERMANY8
HUNGARY11
ISRAEL3
JAPAN10
POLAND59
UNITED KINGDOM4
UNITED STATES4
08

Study locations

58 sites
  • Nemours DuPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children's Center for Digestive Health Care
    Atlanta, Georgia 30342, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07962, United States
  • Levine Childrens at Atrium Health
    Charlotte, North Carolina 28207, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Penn State Hershey Children's Hospital
    Hershey, Pennsylvania 17033, United States
  • Cook Childrens Medical Center
    Fort Worth, Texas 76104, United States
  • Pediatric Specialists Of Virginia
    Fairfax, Virginia 22031, United States
  • Universitair Kinderziekenhuis Koningin Fabiola
    Brussels, 1020, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • UZ Brussel
    Jette, 1090, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Universitätsklinikum Aachen
    Aachen, 52074, Germany
  • Charite-Universitätsmedizin Berlin - Berlin
    Berlin, 13353, Germany
  • Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitatsklinikum Essen
    Essen, 45147, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Dr. von Haunersches Kinderspital
    Munich, 80337, Germany
  • KUNO Klinik St. Hedwig
    Regensburg, 93049, Germany
  • Universitatsklinikum Ulm
    Ulm, 89075, Germany
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
    Miskolc, 3526, Hungary
  • Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz
    Nyíregyháza, 4400, Hungary
  • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
    Szeged, 6720, Hungary
  • Shamir Medical Center Assaf Harofeh
    Be’er Ya‘aqov, 70300, Israel
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Schneider Children's Medical Center
    Petah Tikva, 4920235, Israel
  • Sheba Medical Center
    Ramat Gan, 30700, Israel
  • Juntendo University Hospital
    Bunkyō City, 113 8431, Japan
  • Gunma University Hospital
    Gunma, 371-0034, Japan
  • Kindai University Nara Hospital
    Ikoma, 630-0293, Japan
  • Kurume University Hospital
    Kurume, 830-0011, Japan
  • Saitama Childrens Medical Center
    Saitama Shi, 330-8777, Japan
  • Miyagi Children's Hospital
    Sendai, 989-3126, Japan
  • National Center for Child Health and Development
    Setagaya Ku, 157 8535, Japan
  • Jichi Medical University Hospital
    Shimotsuke, 329-0498, Japan
  • Mie University Hospital
    Tsu, 514 8507, Japan
  • Szpital im. M. Kopernika
    Gdansk, 80 803, Poland
  • Uniwersytecki Szpital Dzieciecy w Krakowie
    Krakow, 30 663, Poland
  • Korczowski Bartosz Gabinet Lekarski
    Rzeszów, 35-302, Poland
  • GASTROMED Sp. z o.o.
    Torun, 87 100, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, 04 501, Poland
  • Instytut Pomnik Centrum Zdrowia Dziecka
    Warsaw, 04 730, Poland
  • Kazan State Medical University
    Kazan', 420138, Russia
  • Russian National Research Medical University named after N.I.Pirogov
    Moscow, 119571, Russia
  • FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences
    Moscow, 119991, Russia
  • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
    Nizhny Novgorod, 603950, Russia
  • Saratov State Medical University
    Saratov, 410054, Russia
  • Yaroslavl Regional Children's Clinical Hospital
    Yaroslavl, 150032, Russia
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
  • University Hospitals Bristol and Weston NHS Foundation Trust
    Bristol, BS2 8BJ, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB2 0QQ, United Kingdom
  • Royal London Hospital
    London, E1 2AT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in May 2025, 49 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion. A results delay was requested in May 2026.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 49 months is close to that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2020
First posted
Nov 16, 2020
StartActual
Mar 17, 2021
Primary completionActual
May 8, 2025
CompletionActual
Jun 5, 2025
Results delay requested
May 7, 2026
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Primary outcomes
9 edited
What changed in the outcomes
  • EditedGlobal: NumberPercentage of Participants withWith Clinical Remission at Induction Week 8 (I-8) VisitTime frame: Week 8 → Induction Week 8
  • EditedNumber of Participants withWith Treatment-emergent Adverse Events (AEsTEAEs) as a Measure of Safety and TolerabilityTime frame: Up to 74 weeks → Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)
  • EditedNumber of Participants withWith Treatment Emergent Serious Adverse Events (SAEsTESAEs) as a Measure of Safety and TolerabilityTime frame: Up to 74 weeks → Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  • EditedNumber of Participants withWith AEs Leading to Discontinuation of Study InterventionTime frame: Up to 74 weeks → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
  • EditedNumber of Participants with AEsWith Adverse Events of Special Interest (AESIAESIs) as a Measure of Safety and TolerabilityTime frame: Up to 74 weeks → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  • EditedNumber of Participants withWith Abnormalities in Clinical Laboratory AbnormalitiesParameters: HematologyTime frame: Up to 74 weeks → Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  • EditedNumber of Participants With Reactions Temporally Associated with anWith Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-siteSite Reactions (Maintenance Period)Time frame: Up to 74 weeks → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  • EditedSerum Concentration of UstekinumabUstekinumab ConcentrationsTime frame: Up to 74 weeks → Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44
  • ChangedBefore US Specific: Clinical Remission at M-44 for Participants who are in Clinical Response at I-8Now Number of Participants With Abnormalities in Clinical Laboratory Parameters: ChemistryTime frame: Week 52 → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Oct 20, 2026
Documents
Secondary outcomes
10 edited, 3 added, 4 removed
What changed in the outcomes
  • EditedNumberPercentage of Participants With Clinical Response at I-Induction Week 8 VisitTime frame: Week 8 → Induction Week 8
  • EditedNumberPercentage of Participants withWith Symptomatic Remission at I-Induction Week 8 VisitTime frame: Week 8 → Induction Week 8
  • EditedPercentage of Participants With Clinical Remission at I-Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) ScoreTime frame: Week 8 → Induction Week 8
  • EditedHistologic-endoscopic MucosalPercentage of Participants With Endoscopic Improvement at Induction Week I-8Time frame: Week 8 → Induction Week 8
  • EditedNumberPercentage of Participants withWith Clinical Remission at Maintenance Week 44 (M-44) VisitTime frame: Week 52 → Maintenance Week 44 (Study Week 52)
  • EditedNumberPercentage of Participants withWith Symptomatic Remission at M-Maintenance Week 44 VisitTime frame: Week 52 → Maintenance Week 44 (Study Week 52)
  • EditedPercentage of Participants With Clinical Remission at M-Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) ScoreTime frame: Week 52 → Maintenance Week 44 (Study Week 52)
  • EditedPercentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week M-44Time frame: Week 52 → Maintenance Week 44 (Study Week 52)
  • EditedPercentage of Participants With Clinical Remission at M-Maintenance Week 44 and notNot Receiving Corticosteroids for atAt Least 90 Days Prior to M-Maintenance Week 44 Among Participants whoWho Received Corticosteroids at M-Induction Week 0Time frame: Week 52 → Maintenance Week 44 (Study Week 52)
  • EditedPercentage of Participants With Histologic-endoscopicEndoscopic Mucosal Improvement at Induction Week M-448Time frame: Week 52 → Induction Week 8
  • AddedPercentage of Participants With Endoscopic Improvement at Maintenance Week 44Time frame: Maintenance Week 44 (Study Week 52)
  • AddedPercentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8Time frame: Maintenance Week 44 (Study Week 52)
  • AddedPercentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44Time frame: Maintenance Week 44 (Study Week 52)
  • RemovedEndoscopic Improvement at I-8 VisitTime frame: Week 8
  • RemovedEndoscopic Improvement at M-44 VisitTime frame: Week 52
  • RemovedClinical Remission at M-44 for Participants who are in Clinical Remission at I-8Time frame: Week 52
  • RemovedUS Specific: Number of Participants with Clinical Remission at I-8 VisitTime frame: Week 8
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Primary outcomes 9 edited
    What changed in the outcomes
    • EditedGlobal: NumberPercentage of Participants withWith Clinical Remission at Induction Week 8 (I-8) VisitTime frame: Week 8 → Induction Week 8
    • EditedNumber of Participants withWith Treatment-emergent Adverse Events (AEsTEAEs) as a Measure of Safety and TolerabilityTime frame: Up to 74 weeks → Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)
    • EditedNumber of Participants withWith Treatment Emergent Serious Adverse Events (SAEsTESAEs) as a Measure of Safety and TolerabilityTime frame: Up to 74 weeks → Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
    • EditedNumber of Participants withWith AEs Leading to Discontinuation of Study InterventionTime frame: Up to 74 weeks → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
    • EditedNumber of Participants with AEsWith Adverse Events of Special Interest (AESIAESIs) as a Measure of Safety and TolerabilityTime frame: Up to 74 weeks → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
    • EditedNumber of Participants withWith Abnormalities in Clinical Laboratory AbnormalitiesParameters: HematologyTime frame: Up to 74 weeks → Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
    • EditedNumber of Participants With Reactions Temporally Associated with anWith Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-siteSite Reactions (Maintenance Period)Time frame: Up to 74 weeks → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
    • EditedSerum Concentration of UstekinumabUstekinumab ConcentrationsTime frame: Up to 74 weeks → Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44
    • ChangedBefore US Specific: Clinical Remission at M-44 for Participants who are in Clinical Response at I-8Now Number of Participants With Abnormalities in Clinical Laboratory Parameters: ChemistryTime frame: Week 52 → Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
    Secondary outcomes 10 edited, 3 added, 4 removed
    What changed in the outcomes
    • EditedNumberPercentage of Participants With Clinical Response at I-Induction Week 8 VisitTime frame: Week 8 → Induction Week 8
    • EditedNumberPercentage of Participants withWith Symptomatic Remission at I-Induction Week 8 VisitTime frame: Week 8 → Induction Week 8
    • EditedPercentage of Participants With Clinical Remission at I-Induction Week 8 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) ScoreTime frame: Week 8 → Induction Week 8
    • EditedHistologic-endoscopic MucosalPercentage of Participants With Endoscopic Improvement at Induction Week I-8Time frame: Week 8 → Induction Week 8
    • EditedNumberPercentage of Participants withWith Clinical Remission at Maintenance Week 44 (M-44) VisitTime frame: Week 52 → Maintenance Week 44 (Study Week 52)
    • EditedNumberPercentage of Participants withWith Symptomatic Remission at M-Maintenance Week 44 VisitTime frame: Week 52 → Maintenance Week 44 (Study Week 52)
    • EditedPercentage of Participants With Clinical Remission at M-Maintenance Week 44 as Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) ScoreTime frame: Week 52 → Maintenance Week 44 (Study Week 52)
    • EditedPercentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week M-44Time frame: Week 52 → Maintenance Week 44 (Study Week 52)
    • EditedPercentage of Participants With Clinical Remission at M-Maintenance Week 44 and notNot Receiving Corticosteroids for atAt Least 90 Days Prior to M-Maintenance Week 44 Among Participants whoWho Received Corticosteroids at M-Induction Week 0Time frame: Week 52 → Maintenance Week 44 (Study Week 52)
    • EditedPercentage of Participants With Histologic-endoscopicEndoscopic Mucosal Improvement at Induction Week M-448Time frame: Week 52 → Induction Week 8
    • AddedPercentage of Participants With Endoscopic Improvement at Maintenance Week 44Time frame: Maintenance Week 44 (Study Week 52)
    • AddedPercentage of Participants With Clinical Remission at Week 44 (Maintenance Period) Who Had Clinical Remission at Induction Week 8Time frame: Maintenance Week 44 (Study Week 52)
    • AddedPercentage of Participants With Histologic-Endoscopic Mucosal Improvement at Maintenance Week 44Time frame: Maintenance Week 44 (Study Week 52)
    • RemovedEndoscopic Improvement at I-8 VisitTime frame: Week 8
    • RemovedEndoscopic Improvement at M-44 VisitTime frame: Week 52
    • RemovedClinical Remission at M-44 for Participants who are in Clinical Remission at I-8Time frame: Week 52
    • RemovedUS Specific: Number of Participants with Clinical Remission at I-8 VisitTime frame: Week 8
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04630028
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
Mar 17, 2021
Primary completion
May 8, 2025
Completion
Jun 5, 2025
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ustekinumab

Start the discussion